Why Aren’t There More Cancer Treatments for Children?
Despite the promise of precision medicine and improved outcomes for individuals diagnosed with cancers, there remains a disconnect between advances in treatment and ensuring access to treatment innovations. Many organizations and academic medical centers have endeavored to take on oncology through research and development of new therapies, collaborative clinical trials, and expanded services and support to cancer patients, survivors and families. Yet even the most advanced treatment programs will fall short if they neglect to address key social determinants of health. Learn how the startup community, tech, social sector, and higher education are ensuring the most vulnerable populations benefit from clinical innovation. <br><br>
- Gwen Nichols, M.D., Chief Medical Officer, The Leukemia & Lymphoma Society<br>
- Sam Volchenboum, MD, PHD, MS, University of Chicago, LLS PedAL Bioinformatics Lead<br>
- Jeffrey Rubnitz, MD, PhD, Director, Leukemia/Lymphoma Division, St. Jude Children’s Research Hospital<br>
- Julie Guillot, AML Parent and LLS PedAL Partnership Outreach Chair